BioCentury
ARTICLE | Clinical News

Velcade bortezomib: Phase II data; approved in U.S

June 30, 2003 7:00 AM UTC

Previous reported results from the open-label Phase II SUMMIT trial showed 67 of 193 (35%) evaluable patients had a complete, partial or minimal response to Velcade alone. Included in the 67 patients ...